Type 2 diabetes (T2D) has an extremely high prevalence in the top five European markets (France, Germany, Italy, Spain, UK). Low-cost metformin (Merck KgaA’s Glucophage, generics) is entrenched as first-line treatment; however, high-cost SGLT-2 inhibitors, GLP-1 receptor agonists, DPP-IV inhibitors and insulin analogues jostle for later-line treatment positioning, while near-term emerging therapies such as semaglutide oral (Novo Nordisk) and tirzepatide (Eli Lilly) have the potential to make significant advancements in treatment of T2D. As competition continues to increase in this dynamic market, cost-conscious payers demand unequivocal evidence of clinical improvements and/or economic benefits on well-defined endpoints to ensure favorable pricing and reimbursement terms, and, therefore, optimal market access. This research examines the current impact of payer policy on prescribing, and probes how payers and prescribers will react to novel agents that, while potentially innovative, will drive up healthcare costs considerably.
European Access & Reimbursement provides integrated brand-level and country-specific analysis of primary market research conducted with payers and prescribers, examining reimbursement dynamics and evaluating the impact of payer policy on prescribing behavior.
France, Germany, Italy, Spain, United Kingdom
KEY DRUGS COVERED
SGLT-2 inhibitors (e.g. Forxiga and emerging agent Steglatro), DPP-IV inhibitors (e.g. Januvia), GLP-1 receptor agonists (e.g. Victoza and emerging agent semaglutide), long-acting insulins (e.g. Lantus), rapid-acting insulins (e.g. Novolog).